Katzenell Dimant represents Dermipsor Ltd. in its acquisition (reverse merger) by Nextgen Biomed Ltd.
In the framework of the transaction Dermipsor’s shareholders sold approximately 100% of their shareholdings in Dermipsor in exchange for shares of the Nextgen Biomed.